HealthEquity (NASDAQ:HQY) Stock

HEALTHEQUITY INC

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

HealthEquity Inc

Revealing a significant insider sell on July 8, Henry Michael Fiore, EVP at HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001428336/000141588925019485//Archives/edgar/data/1428336/000141588925019485/0001415889-25-019485-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Fiore executed a sale of 1,794 shares of HealthEquity with a total value of $182,498.
As of Wednesday morning, HealthEquity shares are down by 1.77%, currently priced at $101.29.
<h3>Discovering HealthEquity: A Closer Look</h3>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>A Deep Dive into HealthEquity's Financials</h3>
Revenue Growth: HealthEquity displayed positive results in 3 months. As of 30 April, 2025, the company achieved a solid revenue growth rate of approximately 15.04%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 67.8%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): HealthEquity's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.62.
</li>
</ul>
Debt Management: HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: HealthEquity's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 75.27.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 7.37 is above industry norms, reflecting an elevated valuation for HealthEquity's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): HealthEquity's EV/EBITDA ratio of 25.64 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001428336">Check Out The Full List Of HealthEquity's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Insider Selling: Henry Michael Fiore Unloads $182K Of HealthEquity Stock

Raymond James analyst C. Gregory Peters reiterates HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Strong Buy and raises the price target from $115 to $120.

Price Target

Reiteration

Analyst Ratings

Raymond James Reiterates Strong Buy on HealthEquity, Raises Price Target to $120

HealthEquity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has fallen 11.68% since its last report. The company recently reported that it has 5.26 million shares sold short, which is 7.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751983232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HealthEquity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About HealthEquity?

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 1.37% on an annualized basis producing an average annual return of 12.85%. Currently, HealthEquity has a market capitalization of $9.09 billion. 
Buying $1000 In HQY: If an investor had bought $1000 of HQY stock 10 years ago, it would be worth $3,276.48 today based on a price of $104.88 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751064312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 12.04%. Currently, HealthEquity has a market capitalization of $8.84 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $315.69 today based on a price of $102.00 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750280431_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

U.S. stocks settled higher on Friday, with the Dow Jones index gaining more than 400 points during the session following the release of jobs data.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul class="wp-block-list">
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated an Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a price target of $500 on June 4. This analyst sees around 6% upside in the stock.</li>
<li>Recent News: CrowdStrike CEO George Kurtz recently expressed confidence in the cybersecurity company's financial practices, as the firm faces a Department of Justice inquiry related to last year's massive global IT outage and transaction reporting.</li>
</ul>
Analyst: Alexander Paris
<ul class="wp-block-list">
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Outperform rating on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) and raised the price target from $112 to $125 on June 5. This analyst sees around 12% surge in the stock.</li>
<li>Recent News: On June 3, HealthEquity reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance.</li>
</ul>
Analyst: Doug Anmuth 
<ul class="wp-block-list">
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and increased the price target from $225 to $240 on June 4. This analyst sees around 12% upside in the stock.</li>
<li>Recent News: On June 5, Amazon.com cut jobs in its books division, including roles at Goodreads and Kindle.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Neutral rating on LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) and cut the price target from $100 to $93 on June 5. This analyst sees around 90% upside in the stock.</li>
<li>Recent News: On June 4, LGI Homes reported 416 home closings in May.</li>
</ul>
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and boosted the price target from $267 to $295 on June 6. This analyst sees around 20% upside in the stock.</li>
<li>Recent News: On June 5, Broadcom reported second-quarter revenue of $15 billion, beating analyst estimates of $14.99 billion, according to Benzinga Pro.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Markets

AMZN

AVGO

CRWD

LGIH

5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Week

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barrington Research raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $112 to $125. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares closed at $113.6 on Wednesday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from $100 to $115. Mizuho analyst David Bellinger maintained a Neutral rating. Five Below shares closed at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $124 to $130. Mizuho analyst Vijay Rakesh maintained an Outperform rating. Micron shares closed at $103.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $80 to $96. Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating. Dollar Tree Enterprise shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased the price target for Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from $86 to $103. B of A Securities analyst Omar Dessouky maintained a Buy rating. Roblox shares closed at $91.05 on Wednesday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) price target from $107 to $122. Goldman Sachs analyst Kate McShane maintained a Buy rating. Five Below shares settled at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) price target from $134 to $145. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. BioNTech shares closed at $111.14 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) price target from $8 to $9. DA Davidson analyst Clark Wright maintained a Neutral rating. Sprinklr shares closed at $9.06 on Wednesday.  <a href="https://www.benzinga.com/quote/CXM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from $23 to $22. Barclays analyst Adrienne Yih maintained an Overweight rating. Victoria&#8217;s Secret shares settled at $20.47 on Wednesday. <a href="https://www.benzinga.com/quote/VSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $52 to $59. Scotiabank analyst Brandon Bingham maintained a Sector Perform rating. Williams shares closed at $60.10 on Wednesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CRWD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MU/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png" alt="" class="wp-image-940314" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

BNTX

DLTR

FIVE

RBLX

VSCO

Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $125.

Barrington Research Maintains Outperform on HealthEquity, Raises Price Target to $125

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $98 to $115.

Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $115

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) posted better-than-expected first-quarter results after Tuesday&#8217;s closing bell.
HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
"The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year," said Scott Cutler, CEO of HealthEquity.
HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74 to a new range of $3.61 to $3.78, versus the $3.63 analyst estimate. The company reiterated its 2026 revenue outlook for a range of $1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HealthEquity shares gained 9.8% to $113.94 on Wednesday.
These analysts made changes to their price targets on HealthEquity following earnings announcement.
<ul class="wp-block-list">
<li>JMP Securities analyst Constantine Davides maintained HealthEquity with a Market Outperform and raised the price target from $110 to $117.</li>
<li>B of A Securities analyst Allen Lutz maintained the stock with a Buy and raised the price target from $110 to $125.</li>
<li>RBC Capital analyst Daniel Perlin maintained HealthEquity with an Outperform rating and raised the price target from $112 to $117.</li>
<li>Goldman Sachs analyst David Roman maintained HealthEquity with a Neutral and raised the price target from $94 to $104.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

HealthEquity Analysts Boost Their Forecasts After Upbeat Earnings

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and raises the price target from $94 to $104.

Goldman Sachs Maintains Neutral on HealthEquity, Raises Price Target to $104

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results. Also, multiple firms raised their respective <a href="https://www.benzinga.com/quote/GWRE/earnings">price targets on the stock</a>.
Guidewire Software reported quarterly earnings of 88 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $293.51 million which beat the analyst consensus estimate of $286.39 million.
Guidewire Software shares jumped 19.1% to $259.83 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Ctrl Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares jumped 54% to $50.67.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 27.8% to $8.71 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 22.7% to $12.58.</li>
<li>REV Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) rose 16.7% to $43.45 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.8% to $36.05.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) rose 15.2% to $17.05 after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) jumped 15.2% to $3.1800.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 13.5% to $6.74. Navitas Semiconductor recently announced it has entered a partnership with BrightLoop for hydrogen fuel-cell charge.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) gained 11.1% to $28.50.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 10% to $670.00. Regencell Bioscience recently announced a 38-for-1 forward stock split.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) gained 9.2% to $113.30 after the company reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) rose 8.6% to $79.70.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 7.5% to $83.47 after the company raised its fourth-quarter guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 7.5% to $3.7997.</li>
</ul>
Now Read This<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

APLD

GWRE

LITE

MCTR

NVTS

REVG

YEXT

ZLAB

Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS raised Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) price target from $120 to $128. UBS analyst Michael Lasser maintained a Buy rating. Dollar General shares closed at $112.62 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/DG/analyst-ratings">view this stock</a>.</li>
<li>Mizuho boosted the price target for Viper Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) from $54 to $55. Mizuho analyst William Janela maintained an Outperform rating. Viper Energy shares closed at $41.41 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/VNOM/analyst-ratings">view this stock</a>.</li>
<li>Goldman Sachs raised XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) price target from $17 to $23. Goldman Sachs analyst Tito Labarta upgraded the stock from Neutral to Buy. XP shares closed at $19.33 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/XP/analyst-ratings">view this stock</a>.</li>
<li>UBS raised the price target for Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from $16 to $18. UBS analyst David Vogt maintained a Neutral rating. Hewlett Packard Enterprise shares closed at $17.68 on Tuesday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital increased the price target for Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) from $189 to $231. RBC Capital analyst Mike Dahl maintained an Outperform rating. Ferguson shares closed at $211.53 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) price target from $135 to $160. B of A Securities analyst Brad Sills maintained an Underperform rating. Guidewire shares settled at $218.13 on Tuesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) price target from $100 to $130. Wells Fargo analyst Joe O&#8217;Dea maintained an Overweight rating. Johnson Controls shares closed at $101.18 on Tuesday. <a href="https://www.benzinga.com/quote/JCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $110 to $117. JMP Securities analyst Constantine Davides maintained a Market Outperform rating. HealthEquity shares closed at $103.76 on Tuesday.  <a href="https://www.benzinga.com/quote/hqy/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) from $70 to $75. Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating. Signet shares settled at $75.24 on Tuesday. <a href="https://www.benzinga.com/quote/sig/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $83 to $90. B of A Securities analyst Erika Najarian maintained a Buy rating. Wells Fargo shares closed at $75.65 on Tuesday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/WFC/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png" alt="" class="wp-image-938410" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

FERG

VNOM

Wells Fargo To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.

RBC Capital analyst Daniel Perlin maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $117.

RBC Capital Maintains Outperform on HealthEquity, Raises Price Target to $117

10 analysts have shared their evaluations of HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $110.9, with a high estimate of $125.00 and a low estimate of $94.00. Observing a downward trend, the current average is 1.47% lower than the prior average price target of $112.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1749045618_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of HealthEquity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$117.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>All You Need to Know About HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Financial Milestones: HealthEquity's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.46%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HealthEquity's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.76%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 10 Analysts

B of A Securities analyst Allen Lutz maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $110 to $125.

B of A Securities Maintains Buy on HealthEquity, Raises Price Target to $125

JMP Securities analyst Constantine Davides maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Market Outperform and raises the price target from $110 to $117.

JMP Securities Maintains Market Outperform on HealthEquity, Raises Price Target to $117

HealthEquity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has fallen 6.83% since its last report. The company recently reported that it has 5.82 million shares sold short, which is 7.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749042030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HealthEquity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Earnings

Health Care

After-Hours Center

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

Legal

Press Releases

If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

Financing

HealthEquity Community Foundation Awards $35,000 in New Grants

HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

Comments

HealthEquity

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL